Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2015 Dec 22:1:34.
doi: 10.1186/s40780-015-0035-2. eCollection 2015.

Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events

Mitsuhiro Nakamura  1 , Ryogo Umetsu  2 , Junko Abe  3 , Toshinobu Matsui  1 , Natsumi Ueda  1 , Yamato Kato  1 , Sayaka Sasaoka  1 , Kohei Tahara  4 , Hirofumi Takeuchi  4 , Yasutomi Kinosada  5
Affiliations
Case Reports

Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events

Mitsuhiro Nakamura et al. J Pharm Health Care Sci. .

Abstract

Background: Bisphosphonates (BPs) are potent antiresorptive agents used to treat osteoporosis and the complications associated with malignant bone metastasis. The aim of this study was to evaluate the incidence of bisphosphonate-related osteonecrosis of the jaw (BRONJ) using the Japanese Adverse Drug Event Report (JADER) database. In particular, we focused on the time-to-onset profile of BRONJ.

Findings: We analyzed reports of BRONJ in the JADER database and calculated the reporting odds ratio (ROR) of BPs potentially associated with BRONJ. We applied the weibull shape parameter to time-to-event data in JADER. The drugs selected for this investigation were seven BPs approved in Japan (alendronate [intraveneous, I.V.], pamidronate, and zoledronate as I.V. BPs; and alendronate (oral), etidronate, minodronate, and risedronate as oral BPs). We analyzed reports of BRONJ events associated with BPs in the JADER database from April 2004 to November 2014. The median value of BRONJ cases caused by alendronate (I.V.), pamidronate, zoledronate, alendronate (oral), etidronate, minodronate, and risedronate were 1342, 812, 486, 863, 1461, 432, and 730 days, respectively. The lower 95 % confidence interval of the Weibull-shape parameter β for I.V. BPs (pamidronate and zoledronate) exceeded 1. The risk of BRONJ with I.V. BPs increased over time.

Conclusion: Thus, the incidence of BRONJ with BP treatment should be closely monitored for a 3-year period. Further studies are required to draw conclusions, and we believe that this information about BRONJ induced by BPs will prove beneficial to patients and pharmacists.

Keywords: Bisphosphonate; Japanese adverse drug event report database; Osteonecrosis of jaw.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Two by two table used for the calculation of reporting odds ratios
Fig. 2
Fig. 2
Histogram and Weibull shape parameter of BRONJ for (a) alendronate (Intravenous), (b) pamidronate, (c) zoledronate, (d) alendronate (oral), (e) etidronate, (f) minodronate and (g) risedronate
Fig. 3
Fig. 3
Histogram and Weibull shape parameter of BRONJ stratified by formulations and dosages for (a) pamidronate (30−45mg), (b) pamidronate (90mg), (c) zoredronate (4mg), (d) alendronate (oral) (5mg), (e) alendronate (oral) (35mg), (f) risedronate (2.5mg) and (g) risedronate (17.5mg)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ruggiero LS. Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ) Clin Cases Miner Bone Metab. 2007;4:37–42. - PMC - PubMed
    1. Ruggiero LS, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of Jaw - 2009 Update. Aust Endod J. 2009;35:119–30. doi: 10.1111/j.1747-4477.2009.00213.x. - DOI - PubMed
    1. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw −2014 update. J Oral Maxillofac Surg. 2014;72:1938–56. doi: 10.1016/j.joms.2014.04.031. - DOI - PubMed
    1. Mariotti A. Bisphosphonates and osteonecrosis of the jaws. J Dent Educ. 2008;72:919–29. - PubMed
    1. Umetsu R, Nishibata Y, Abe J, Suzuki Y, Hara H, Nagasawa H, et al. Evaluation of the association between the use of oral anti-hyperglycemic agents and hypoglycemia in Japan by data mining of the Japanese Adverse Drug Event Report (JADER) database. Yakugaku Zasshi. 2014;134:299–304. doi: 10.1248/yakushi.13-00225. - DOI - PubMed

Publication types